Search for: All records

Hepatitis C virus (HCV), a member of the Flaviviridae family, is an RNA virus enclosed in an envelope that infects approximately 50 million people worldwide. Despite its significant burden on public health, no vaccine is currently available, and many individuals remain unaware of their infection due to the often asymptomatic nature of the disease. Early detection of HCV is critical for initiating curative treatments, which can prevent long-term complications such as cirrhosis, liver cancer, and decompensated liver disease. However, conventional diagnostic approaches available, such as enzyme immunoassays (EIAs) and polymerase chain reaction (PCR)-based methods, are often costly, time-intensive, and challenging to be implemented in resource-limited settings. This review provides an overview of HCV disease and the structural components of the virus, illustrating how different diagnostic methods target various parts of the viral structure. It examines current diagnostic tests and assays, highlighting their mechanisms, applications, and limitations, which necessitates the development of improved detection methods. Additionally, the paper explores emerging technologies in HCV detection that could offer affordable, accessible, and easy-to-use diagnostic solutions, particularly for deployment in low-resource and point-of-care settings. These advancements have the potential to contribute significantly to achieving the World Health Organization’s (WHO) target of eliminating HCV as a public threat by 2030. 

Hepatitis C virus (HCV) infections occur in approximately 3% of the world population. The development of an enhanced and extensive-scale screening is required to accomplish the World Health Organization’s (WHO) goal of eliminating HCV as a public health problem by 2030. However, standard testing methods are time-consuming, expensive, and challenging to deploy in remote and underdeveloped areas. Therefore, a cost-effective, rapid, and accurate point-of-care (POC) diagnostic test is needed to properly manage the disease and reduce the economic burden caused by high case numbers. Herein, we present a fully automated reverse-transcription loop-mediated isothermal amplification (RT-LAMP)-based molecular diagnostic set-up for rapid HCV detection. The set-up consists of an automated disposable microfluidic chip, a small surface heater, and a reusable magnetic actuation platform. The microfluidic chip contains multiple chambers in which the plasma sample is processed. The system utilizes SYBR green dye to detect the amplification product with the naked eye. The efficiency of the microfluidic chip was tested with human plasma samples spiked with HCV virions, and the limit of detection observed was 500 virions/mL within 45 min. The entire virus detection process was executed inside a uniquely designed, inexpensive, disposable, and self-driven microfluidic chip with high sensitivity and specificity.